|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, has been reported to exert its tumor suppressive function via modulation of PTEN expression in many malignancies, including breast cancer (BC).
|
31196157 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcripts derived from the <i>PTEN pseudogene (PTENP1)</i> function as decoys to adsorb miRNAs targeting the <i>PTEN</i> tumor suppressor for degradation, and <i>PTENP1</i> upregulation is known to inhibit growth in preclinical cancer models.
|
29021233 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Exosomal PTENP1 could suppress tumor growth in vivo.
|
30285771 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The relationship between PTENP1 and susceptibility tumors is reported, while, an association of PTENP1 with the risk of oral squamous cell carcinoma (OSCC) in Chinese population is lacked.
|
30229832 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, has been reported to exert its tumor suppressive function via modulation of PTEN expression in many malignancies.
|
28212532 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PTENP1, a pseudogene of PTEN, was previously reported to be a tumour suppressor in some cancer types.
|
28112249 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PTEN pseudogene (PTENP1) has a tumor suppressive role in multiple cancers.
|
28731203 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, was previously reported to be a tumour suppressor in some cancer types.
|
29296207 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these results suggest that PTENP1 functions as a novel tumor suppressor in GC and its suppressive ability may be involved in the modulation of PTEN.
|
25968876 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Injection of the PTENP1-expressing SB-BV vector into mice bearing HCC tumors effectively mitigated the tumor growth, suppressed intratumoral cell proliferation, elicited apoptosis, autophagy and inhibited angiogenesis.
|
25617127 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Somatic mutations were predominantly found within tumor suppressor genes [TP53 (3 cases), PTEN (2 cases), RB1 (1 case)].
|
25446844 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PTENP1 is a pseudogene of the PTEN tumor suppression gene (TSG).
|
25249556 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PTENP1 transcript was expressed in NE, cell lines, and 34/61 (56%) primary tumors.
|
22005521 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a model for the protein-coding-independent role of RNAs, we describe the functional relationship between the mRNAs produced by the PTEN tumour suppressor gene and its pseudogene PTENP1 and the critical consequences of this interaction.
|
20577206 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Detection of PTEN nonsense mutation and psiPTEN expression in central nervous system high-grade astrocytic tumors by a yeast-based stop codon assay.
|
10980610 |
2000 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
G allele of rs7853346 polymorphism in PTENP1 enhances the proliferation of multiple myeloma cancer stem cells by promoting the expression of PTENP1 and its downstream signaling molecules.
|
31338886 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Our study investigated the function of PTENP1 in glioma and provided new insights for treating that malignancy.
|
30613153 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We analyzed PTENP1 and PTEN levels in clinical BC samples and cell lines, and found that PTENP1 and PTEN were confirmed and closely correlated with the malignancy of BC cell lines and poor clinical prognosis.
|
31196157 |
2019 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, has been reported to exert its tumor suppressive function via modulation of PTEN expression in many malignancies.
|
28212532 |
2017 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
We also show that the PTENP1 locus is selectively lost in human cancer.
|
20577206 |
2010 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
We analyzed PTENP1 and PTEN levels in clinical BC samples and cell lines, and found that PTENP1 and PTEN were confirmed and closely correlated with the malignancy of BC cell lines and poor clinical prognosis.
|
31196157 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Our study investigated the function of PTENP1 in glioma and provided new insights for treating that malignancy.
|
30613153 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
GeneticVariation
|
group |
BEFREE |
G allele of rs7853346 polymorphism in PTENP1 enhances the proliferation of multiple myeloma cancer stem cells by promoting the expression of PTENP1 and its downstream signaling molecules.
|
31338886 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |